Welcome to our dedicated page for Acurx Pharmaceuticals SEC filings (Ticker: ACXP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Acurx Pharmaceuticals, Inc.'s SEC filings document a late-stage biopharmaceutical issuer developing antibiotics for difficult-to-treat Gram-positive bacterial infections. Registration statements describe securities offerings, resale registration mechanics, common stock, warrants and the company's status as an emerging growth company and smaller reporting company.
ACXP's Form 8-K filings record material events tied to capital structure, governance and compensation, including amendments to authorized common shares and executive and director compensation arrangements. The filings also cover Nasdaq-listed common stock, operating and financial results, material agreements, shareholder voting matters and risk disclosures associated with antibiotic research and development.
Acurx Pharmaceuticals, Inc. director Thomas L. Harrison received a stock option award as compensation for service on the company’s board of directors. The grant covers 2,150 stock options for common stock at an exercise price of $2.36 per share.
The options were awarded at no upfront cost and will vest on April 20, 2027, meaning they become exercisable on that date. The options are scheduled to expire on April 20, 2036 if not exercised. Following this grant, Harrison holds stock options covering 2,150 shares directly.
Acurx Pharmaceuticals, Inc. director Joseph C. Scodari received a stock option grant related to his service on the company’s board. The award covers 2,150 stock options for common stock at an exercise price of $2.36 per share, with all options vesting on April 20, 2027.
The options expire on April 20, 2036. After this grant, Scodari holds 2,150 stock options directly, reflecting a compensation-related award rather than an open‑market share purchase or sale.
Acurx Pharmaceuticals director Robert J. DeLuccia received a compensation grant of stock options covering 37,100 shares of common stock. The options were granted on April 20, 2026 with an exercise price of $2.36 per share and expire on April 20, 2036.
The options vest in 36 equal monthly installments starting on the grant date, meaning the award vests gradually over three years. Following this grant, DeLuccia holds stock options for 37,100 underlying shares directly, with no additional derivative positions shown in this filing.
Acurx Pharmaceuticals, Inc. reported that President and CEO David P. Luci received a grant of stock options. On April 20, 2026, he was granted options to purchase 37,100 shares of common stock at an exercise price of $2.36 per share.
The options vest in 36 equal monthly installments starting on the grant date and expire on April 20, 2036. Following this grant, he holds 37,100 stock options directly, each tied to one underlying share of Acurx common stock.
Acurx Pharmaceuticals, Inc. reported that its Chief Financial Officer, Robert G. Shawah, received a grant of stock options covering 25,900 shares of common stock on April 20, 2026.
The options have an exercise price of $2.36 per share, expire on April 20, 2036, and vest in 36 equal monthly installments starting on the grant date. After this grant, he holds stock options for 25,900 shares directly as reported in this filing. This is a compensation-related award rather than an open-market share purchase or sale.
Acurx Pharmaceuticals is raising equity capital through a registered direct offering with a concurrent private placement of warrants. The company agreed to sell 816,068 common shares at $3.03 per share and pre-funded warrants for up to 9,017 shares at $3.029, for aggregate gross proceeds of about $2.5 million before fees.
In the private placement, investors will receive Series H warrants to purchase up to 1,650,170 shares of common stock at an exercise price of $2.78 per share, exercisable immediately and expiring 24 months after the resale registration becomes effective. If these warrants are fully exercised for cash, the company could receive up to an additional $4.6 million.
The company plans to use net proceeds for working capital and general corporate purposes, has agreed to a 15-day lock-up on most new equity issuances after closing, and will avoid variable rate transactions for one year except for a potential at-the-market program and an equity line of credit.
Acurx Pharmaceuticals is raising equity capital through a registered direct offering with a concurrent private placement of warrants. The company agreed to sell 816,068 common shares at $3.03 per share and pre-funded warrants for up to 9,017 shares at $3.029, for aggregate gross proceeds of about $2.5 million before fees.
In the private placement, investors will receive Series H warrants to purchase up to 1,650,170 shares of common stock at an exercise price of $2.78 per share, exercisable immediately and expiring 24 months after the resale registration becomes effective. If these warrants are fully exercised for cash, the company could receive up to an additional $4.6 million.
The company plans to use net proceeds for working capital and general corporate purposes, has agreed to a 15-day lock-up on most new equity issuances after closing, and will avoid variable rate transactions for one year except for a potential at-the-market program and an equity line of credit.
Acurx Pharmaceuticals, Inc. is offering 816,068 shares of common stock and pre-funded warrants to purchase up to 9,017 shares of common stock to certain investors at $3.03 per share and $3.029 per pre-funded warrant, respectively. The pre-funded warrants have an exercise price of $0.001 and are immediately exercisable.
The offering assumes full exercise of the pre-funded warrants and would result in approximately 3,680,110 shares outstanding immediately following the offering (as presented). Net proceeds to the company are expected to be approximately $2.2 million, which Acurx intends to use for working capital and general corporate purposes.
Acurx Pharmaceuticals, Inc. is offering 816,068 shares of common stock and pre-funded warrants to purchase up to 9,017 shares of common stock to certain investors at $3.03 per share and $3.029 per pre-funded warrant, respectively. The pre-funded warrants have an exercise price of $0.001 and are immediately exercisable.
The offering assumes full exercise of the pre-funded warrants and would result in approximately 3,680,110 shares outstanding immediately following the offering (as presented). Net proceeds to the company are expected to be approximately $2.2 million, which Acurx intends to use for working capital and general corporate purposes.
Acurx Pharmaceuticals files its annual report describing progress on ibezapolstat, a first‑in‑class oral antibiotic targeting DNA pol IIIC to treat Clostridioides difficile infection (CDI). Phase 2 trials showed a 96% clinical cure rate in 26 treated patients, with rapid eradication of C. difficile and no drug‑related serious adverse events. Microbiome data suggest ibezapolstat preserves beneficial gut bacteria and may lower recurrence compared with vancomycin. The drug holds FDA Qualified Infectious Disease Product and Fast Track designations, supporting an expedited Phase 3 path. Acurx estimates U.S. CDI incidence approaching 600,000 infections annually and projects potential peak‑year sales over $1 billion if approved, reflecting the significant unmet need for recurrence‑reducing CDI therapies.
Acurx Pharmaceuticals is reducing cash compensation and advancing its lead antibiotic program. Effective April 1, 2026, the Compensation Committee approved fully voluntary 10% base salary cuts for senior executives, including the CEO and Executive Chairman, and a 10% cut to cash retainers for non-employee directors, while equity incentives remain unchanged.
The company also launched a new clinical initiative to expand ibezapolstat into recurrent C. difficile infection with an open-label pilot trial in up to 20 multiply‑recurrent patients, with start-up activities later this month and first-patient enrollment expected in the fourth quarter, intended to inform a planned Phase 3 registration trial and a future FDA LPAD approval request.
Acurx Pharmaceuticals, Inc. is registering up to 750,000 shares of common stock for resale by Lincoln Park Capital Fund, LLC under an existing purchase agreement. These shares may be issued to Lincoln Park over a 24‑month period, with Lincoln Park then selling them into the market.
Acurx will not receive proceeds from Lincoln Park’s resales, but may receive up to $7.6 million in aggregate gross proceeds from future sales of stock directly to Lincoln Park under the $12.0 million purchase agreement. As of January 30, 2026, Acurx had 2,546,717 shares outstanding, and operates as a late‑stage biopharmaceutical company developing Gram‑positive‑targeted antibiotics, including for C. difficile and MRSA.